vs
Apellis Pharmaceuticals, Inc.（APLS）与EverQuote, Inc.（EVER）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是EverQuote, Inc.的1.0倍（$199.9M vs $195.3M），EverQuote, Inc.净利率更高（29.6% vs -29.5%，领先59.1%），EverQuote, Inc.同比增速更快（32.5% vs -5.9%），EverQuote, Inc.自由现金流更多（$25.8M vs $-14.3M），过去两年EverQuote, Inc.的营收复合增速更高（46.5% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
EverQuote, Inc.是一家创立于2011年的在线保险比价交易平台，总部位于美国马萨诸塞州剑桥市，致力于连接保险消费者与合适的保险服务商，为用户提供便捷的线上保险选购对接服务。
APLS vs EVER — 直观对比
营收规模更大
APLS
是对方的1.0倍
$195.3M
营收增速更快
EVER
高出38.4%
-5.9%
净利率更高
EVER
高出59.1%
-29.5%
自由现金流更多
EVER
多$40.1M
$-14.3M
两年增速更快
EVER
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $195.3M |
| 净利润 | $-59.0M | $57.8M |
| 毛利率 | — | 97.7% |
| 营业利润率 | -25.6% | 9.5% |
| 净利率 | -29.5% | 29.6% |
| 营收同比 | -5.9% | 32.5% |
| 净利润同比 | -62.2% | 369.3% |
| 每股收益（稀释后） | $-0.40 | $1.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEVER
| Q4 25 | $199.9M | $195.3M | ||
| Q3 25 | $458.6M | $173.9M | ||
| Q2 25 | $178.5M | $156.6M | ||
| Q1 25 | $166.8M | $166.6M | ||
| Q4 24 | $212.5M | $147.5M | ||
| Q3 24 | $196.8M | $144.5M | ||
| Q2 24 | $199.7M | $117.1M | ||
| Q1 24 | $172.3M | $91.1M |
净利润APLSEVER
| Q4 25 | $-59.0M | $57.8M | ||
| Q3 25 | $215.7M | $18.9M | ||
| Q2 25 | $-42.2M | $14.7M | ||
| Q1 25 | $-92.2M | $8.0M | ||
| Q4 24 | $-36.4M | $12.3M | ||
| Q3 24 | $-57.4M | $11.6M | ||
| Q2 24 | $-37.7M | $6.4M | ||
| Q1 24 | $-66.4M | $1.9M |
毛利率APLSEVER
| Q4 25 | — | 97.7% | ||
| Q3 25 | — | 97.3% | ||
| Q2 25 | — | 96.9% | ||
| Q1 25 | — | 96.8% | ||
| Q4 24 | — | 96.3% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 95.7% | ||
| Q1 24 | — | 94.5% |
营业利润率APLSEVER
| Q4 25 | -25.6% | 9.5% | ||
| Q3 25 | 48.7% | 10.1% | ||
| Q2 25 | -18.6% | 9.0% | ||
| Q1 25 | -50.0% | 4.8% | ||
| Q4 24 | -12.3% | 8.2% | ||
| Q3 24 | -24.0% | 8.1% | ||
| Q2 24 | -14.7% | 5.4% | ||
| Q1 24 | -36.0% | 1.9% |
净利率APLSEVER
| Q4 25 | -29.5% | 29.6% | ||
| Q3 25 | 47.0% | 10.8% | ||
| Q2 25 | -23.6% | 9.4% | ||
| Q1 25 | -55.3% | 4.8% | ||
| Q4 24 | -17.1% | 8.3% | ||
| Q3 24 | -29.2% | 8.0% | ||
| Q2 24 | -18.9% | 5.5% | ||
| Q1 24 | -38.5% | 2.1% |
每股收益（稀释后）APLSEVER
| Q4 25 | $-0.40 | $1.53 | ||
| Q3 25 | $1.67 | $0.50 | ||
| Q2 25 | $-0.33 | $0.39 | ||
| Q1 25 | $-0.74 | $0.21 | ||
| Q4 24 | $-0.30 | $0.35 | ||
| Q3 24 | $-0.46 | $0.31 | ||
| Q2 24 | $-0.30 | $0.17 | ||
| Q1 24 | $-0.54 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $171.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $238.0M |
| 总资产 | $1.1B | $326.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSEVER
| Q4 25 | $466.2M | $171.4M | ||
| Q3 25 | $479.2M | $145.8M | ||
| Q2 25 | $370.0M | $148.2M | ||
| Q1 25 | $358.4M | $125.0M | ||
| Q4 24 | $411.3M | $102.1M | ||
| Q3 24 | $396.9M | $82.8M | ||
| Q2 24 | $360.1M | $60.9M | ||
| Q1 24 | $325.9M | $48.6M |
总债务APLSEVER
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSEVER
| Q4 25 | $370.1M | $238.0M | ||
| Q3 25 | $401.2M | $174.9M | ||
| Q2 25 | $156.3M | $170.3M | ||
| Q1 25 | $164.2M | $149.5M | ||
| Q4 24 | $228.5M | $135.4M | ||
| Q3 24 | $237.1M | $117.7M | ||
| Q2 24 | $264.3M | $100.8M | ||
| Q1 24 | $266.7M | $88.3M |
总资产APLSEVER
| Q4 25 | $1.1B | $326.9M | ||
| Q3 25 | $1.1B | $256.1M | ||
| Q2 25 | $821.4M | $241.4M | ||
| Q1 25 | $807.3M | $232.1M | ||
| Q4 24 | $885.1M | $210.5M | ||
| Q3 24 | $901.9M | $180.5M | ||
| Q2 24 | $904.5M | $158.0M | ||
| Q1 24 | $831.9M | $135.4M |
负债/权益比APLSEVER
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $27.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $25.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 13.2% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | 0.47× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $90.3M |
8季度趋势，按日历期对齐
经营现金流APLSEVER
| Q4 25 | $-14.2M | $27.0M | ||
| Q3 25 | $108.5M | $19.8M | ||
| Q2 25 | $4.4M | $25.3M | ||
| Q1 25 | $-53.4M | $23.3M | ||
| Q4 24 | $19.4M | $20.1M | ||
| Q3 24 | $34.1M | $23.6M | ||
| Q2 24 | $-8.3M | $12.4M | ||
| Q1 24 | $-133.0M | $10.4M |
自由现金流APLSEVER
| Q4 25 | $-14.3M | $25.8M | ||
| Q3 25 | $108.3M | $18.5M | ||
| Q2 25 | $4.4M | $23.8M | ||
| Q1 25 | $-53.4M | $22.2M | ||
| Q4 24 | $19.3M | $19.1M | ||
| Q3 24 | — | $22.1M | ||
| Q2 24 | $-8.4M | $11.5M | ||
| Q1 24 | $-133.3M | $9.7M |
自由现金流率APLSEVER
| Q4 25 | -7.1% | 13.2% | ||
| Q3 25 | 23.6% | 10.6% | ||
| Q2 25 | 2.5% | 15.2% | ||
| Q1 25 | -32.0% | 13.3% | ||
| Q4 24 | 9.1% | 13.0% | ||
| Q3 24 | — | 15.3% | ||
| Q2 24 | -4.2% | 9.8% | ||
| Q1 24 | -77.3% | 10.6% |
资本支出强度APLSEVER
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 0.8% |
现金转化率APLSEVER
| Q4 25 | — | 0.47× | ||
| Q3 25 | 0.50× | 1.05× | ||
| Q2 25 | — | 1.72× | ||
| Q1 25 | — | 2.92× | ||
| Q4 24 | — | 1.64× | ||
| Q3 24 | — | 2.04× | ||
| Q2 24 | — | 1.93× | ||
| Q1 24 | — | 5.47× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EVER
| Automotive | $179.9M | 92% |
| Home And Renters | $15.4M | 8% |
